CytomX Therapeutics vs Pyxis Oncology
CTMX and PYXS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CTMX and PYXS compare
CytomX Therapeutics is the larger company, worth 3.4 times as much as Pyxis Oncology ($445M against $132M).
CytomX Therapeutics scores higher on the StockData Score (8 against 5 for Pyxis Oncology), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CTMX | PYXS |
|---|---|---|
| Size and price | ||
| Market cap | $445M | $132M |
| Share price | $2.04 | $1.58 |
| Change, 1 year | −51.8% | −63.8% |
| Change, 5 years | −72.2% | −87.8% |
| Beta (5Y) | 1.59 | 1.61 |
| Employees | 69 | 56 |
| StockData Score | ||
| Total score | 8 (better) | 5 |
| Valuation score | 1 (better) | 0 |
| Growth score | 1 (better) | 0 |
| Performance score | 1 (better) | 0 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 31.7× | – |
| P/B | 1.6× (better) | 3.2× |
| FCF yield | −11.5% | – |
| Growth | ||
| Revenue growth (TTM) | −87.7% | – |
| Revenue growth, 5Y average | 2.2% | – |
| Net income growth (TTM) | −405% | – |
| EPS growth (TTM) | −215% | – |
| Profitability | ||
| Operating margin | −676% | – |
| Net margin | −609% | – |
| FCF margin | −364% | – |
| Return on equity | −43.6% (better) | −158% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 7.82 (better) | 2.96 |
| Altman Z-score | 0.58 (better) | −10.32 |
| Piotroski F-score | 2 (better) | 1 |
| Dividends and buybacks | ||
| Buyback yield | −55.0% | – |
| Shareholder yield | −55.0% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 97.9% | 40.9% |
| Held by insiders | 1.5% | 20.4% |
| Insider net buying, 12 months | −$1.2M | −$107K (better) |
| Short interest, % of float | 21.1% | 6.8% |
Go deeper
- CTMX stock overview
- CTMX income statement
- CTMX valuation and score
- PYXS stock overview
- PYXS income statement
- PYXS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.